Stryker Corporation $SYK Shares Sold by Wendell David Associates Inc.

Wendell David Associates Inc. lessened its stake in shares of Stryker Corporation (NYSE:SYK) by 2.4% in the 2nd quarter, Holdings Channel.com reports. The firm owned 113,603 shares of the medical technology company’s stock after selling 2,820 shares during the quarter. Stryker comprises about 4.5% of Wendell David Associates Inc.’s portfolio, making the stock its 6th largest holding. Wendell David Associates Inc.’s holdings in Stryker were worth $44,945,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of SYK. Sachetta LLC raised its stake in shares of Stryker by 58.7% during the second quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock worth $29,000 after purchasing an additional 27 shares during the last quarter. Goodman Advisory Group LLC purchased a new stake in shares of Stryker during the first quarter worth approximately $32,000. Ridgewood Investments LLC raised its stake in shares of Stryker by 48.4% during the second quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company’s stock worth $36,000 after purchasing an additional 30 shares during the last quarter. Ransom Advisory Ltd purchased a new stake in shares of Stryker during the first quarter worth approximately $37,000. Finally, Smallwood Wealth Investment Management LLC purchased a new stake in shares of Stryker during the first quarter worth approximately $40,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Trading Up 1.5%

Shares of SYK stock opened at $374.67 on Friday. Stryker Corporation has a fifty-two week low of $329.16 and a fifty-two week high of $406.19. The stock has a market cap of $143.24 billion, a P/E ratio of 49.63, a P/E/G ratio of 2.70 and a beta of 0.94. The business has a fifty day simple moving average of $379.40 and a 200-day simple moving average of $378.77. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, beating analysts’ consensus estimates of $3.07 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The business had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $5.92 billion. During the same quarter last year, the business posted $2.81 earnings per share. The business’s revenue for the quarter was up 11.1% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be paid a dividend of $0.84 per share. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.9%. Stryker’s dividend payout ratio (DPR) is presently 44.50%.

Analyst Upgrades and Downgrades

Several research firms have recently commented on SYK. UBS Group set a $408.00 price target on Stryker in a research note on Monday, October 13th. Wall Street Zen upgraded Stryker from a “hold” rating to a “buy” rating in a research report on Saturday. Evercore ISI cut their price objective on Stryker from $418.00 to $410.00 and set an “outperform” rating for the company in a research report on Tuesday, October 7th. Rothschild Redb upgraded Stryker to a “hold” rating in a research report on Thursday, September 18th. Finally, Weiss Ratings reiterated a “buy (b-)” rating on shares of Stryker in a research report on Wednesday, October 8th. Fifteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, Stryker has an average rating of “Moderate Buy” and a consensus target price of $431.76.

Insiders Place Their Bets

In related news, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the sale, the director owned 3,222,108 shares of the company’s stock, valued at $1,212,962,556.60. This trade represents a 5.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Viju Menon sold 500 shares of the stock in a transaction on Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the sale, the insider directly owned 12,511 shares in the company, valued at approximately $4,886,921.71. The trade was a 3.84% decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by company insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.